Veldmar Closes $22M Bought-Deal Financing

Veldmar Therapeutics has closed its previously announced bought-deal offering for gross proceeds of $22.0M.

TORONTO, ON — June 18, 2026 — Veldmar Therapeutics Ltd. (TSXV: VLDM) Veldmar Therapeutics Ltd. (TSXV: VLDM) has closed its previously announced bought-deal offering of 8.8M units at $2.50 per unit for gross proceeds of $22.0M.

About Veldmar Therapeutics Ltd.

Pre-revenue oncology developer. Shares auditor and a scientific officer with Cascade BioSciences. Recently filed a bought-deal financing. Veldmar Therapeutics Ltd. is incorporated under the laws of Canada (federal) and its common shares trade on the TSX Venture Exchange under the symbol "VLDM". The Company's head office is located at 120 Adelaide St W, Suite 2400, Toronto, ON M5H 1T1.

Cautionary Note Regarding Forward-Looking Information

This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information relates to future events or future performance and includes, without limitation, statements regarding Veldmar Therapeutics Ltd.'s expectations, plans, objectives, assumptions, intentions or beliefs regarding future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by the forward-looking information. Readers are cautioned not to place undue reliance on such statements, which speak only as of the date of this news release. Except as required by applicable securities laws, Veldmar Therapeutics Ltd.undertakes no obligation to update or revise any forward-looking information.

For further information

Julien Arsenault

Chief Financial Officer

Veldmar Therapeutics Ltd.

+1 416·555·0012

ir@veldmarthe.ca

— 30 —

News Release · June 18, 2026Page 1 of 1